{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Insight Exchange by L.E.K. Consulting","title":"Scope 3 Emissions: A Strategic Imperative for Pharma Companies","html":"","width":"100%","height":180,"duration":1148,"description":"In this episode of “Insight Exchange,” we explore the crucial role of Scope 3 emissions reduction in the pharmaceutical industry. Listen to L.E.K. Consulting experts Verena Ahnert and Max Cambras, who share their insights on the significance of Scope 3 emissions, the current state of commitments in pharma and how emissions reduction is both a strategic consideration and mutually beneficial to both pharma and the environment.\nKey points/topics covered:Explanation of Scope 3 emissions and their importance in pharma\nThe current state of Scope 3 commitments in the pharmaceutical industry\nKey drivers of Scope 3 emissions in pharma\nThe strategic co-benefits of Scope 3 emissions reduction in the pharmaceutical industry\nThe path to achieving strategic co-benefits through emissions reduction in pharma\nTune in for a deep dive into a pressing environmental issue that’s reshaping the pharma industry’s strategies and operations.\nInterested in learning more? Read our Special Report, Scope 3 Emissions: A Strategic Imperative for Pharma Companies.\nConnect with our experts on LinkedIn:\nVerena Ahnert, Partner, L.E.K. Consulting: https://www.linkedin.com/in/verena-ahnert-7a449a2/\nMax Cambras, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/max-cambras-08348411/","thumbnail_url":"https://img.transistorcdn.com/7xyTv3om737tuz9514TO6-LkcYNrLpoXnZyZxPVyggk/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzI2MjQ5LzE2NDI1/Mjg4NDAtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}